Literature DB >> 25913132

Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer.

Melissa Hodeib1, Jenny Chang2, Fong Liu3, Argyrios Ziogas2, Sarah Dilley4, Leslie M Randall3, Hoda Anton-Culver2, Robert E Bristow3.   

Abstract

OBJECTIVE: Investigate the impact of socioeconomic status and other demographic variables on adherence to the National Comprehensive Cancer Network ovarian cancer treatment guidelines among patients with stage I/II disease.
METHODS: Patients diagnosed with stage I/II epithelial ovarian cancer between 1/1/96-12/31/06 were identified from the California Cancer Registry. Univariate analysis and multivariate logistic regression models were used to evaluate differences in surgical procedures, chemotherapy regimens, and overall adherence to the NCCN guidelines according to increasing SES quintiles (SES-1 to SES-5).
RESULTS: A total of 5445 stage I and II patients were identified. The median age at diagnosis was 54.0years (range=18-99years); 72.5% of patients had stage I disease, while 27.5% had stage II disease. With a median follow-up time of 5years, the 5-year ovarian cancer-specific survival for all patients was 82.7% (SE=0.6%). Overall, 23.7% of patients received care that was adherent to the NCCN guidelines. Compared to patients in the highest SES quintile (SES-5), patients in the lowest SES quintile (SES-1) were significantly less likely to receive proper surgery (27.3% vs 47.9%, p<0.001) or chemotherapy (42.4% vs 53.6%, p<0.001). There were statistically significant trends between increasing SES and the likelihood of overall treatment plan adherence to the NCCN guidelines: SES-1=16.4%, SES-2=19.0%, SES-3=22.4%, SES-4=24.2% and SES-5=31.6% (p<0.001). Multivariate logistic regression analysis revealed that compared to SES-5, decreasing SES was independently predictive of a higher risk of non-standard overall care.
CONCLUSIONS: For patients with early-stage ovarian cancer, low SES is a significant and independent predictor of deviation from the NCCN guidelines for surgery, chemotherapy, and overall treatment. Published by Elsevier Inc.

Entities:  

Keywords:  Adherent care; NCCN; Ovary cancer; Socioeconomic status

Mesh:

Year:  2015        PMID: 25913132      PMCID: PMC5145799          DOI: 10.1016/j.ygyno.2015.04.011

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  19 in total

1.  Socioeconomic status and breast cancer incidence in California for different race/ethnic groups.

Authors:  K Yost; C Perkins; R Cohen; C Morris; W Wright
Journal:  Cancer Causes Control       Date:  2001-10       Impact factor: 2.506

2.  Insurance status and the use of guideline therapy in the treatment of selected cancers.

Authors:  Linda C Harlan; Amanda L Greene; Limin X Clegg; Margaret Mooney; Jennifer L Stevens; Martin L Brown
Journal:  J Clin Oncol       Date:  2005-11-21       Impact factor: 44.544

3.  The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm.

Authors:  Robert E Bristow; Bryan E Palis; Dennis S Chi; William A Cliby
Journal:  Gynecol Oncol       Date:  2010-06-22       Impact factor: 5.482

4.  Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States.

Authors:  Linda C Harlan; Limin X Clegg; Edward L Trimble
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

5.  Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.

Authors:  Robert E Bristow; Matthew A Powell; Noor Al-Hammadi; Ling Chen; J Philip Miller; Phillip Y Roland; David G Mutch; William A Cliby
Journal:  J Natl Cancer Inst       Date:  2013-03-28       Impact factor: 13.506

6.  Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes.

Authors:  Robert E Bristow; Marianna L Zahurak; Teresa P Diaz-Montes; Robert L Giuntoli; Deborah K Armstrong
Journal:  Gynecol Oncol       Date:  2009-09-18       Impact factor: 5.482

7.  Racial disparities in the treatment of advanced epithelial ovarian cancer.

Authors:  Elizabeth A Howell; Natalia Egorova; Monica P Hayes; Juan Wisnivesky; Rebeca Franco; Nina Bickell
Journal:  Obstet Gynecol       Date:  2013-11       Impact factor: 7.661

8.  Validation of self-reported cancers in the California Teachers Study.

Authors:  Arti Parikh-Patel; Mark Allen; William E Wright
Journal:  Am J Epidemiol       Date:  2003-03-15       Impact factor: 4.897

9.  Predictors of comprehensive surgical treatment in patients with ovarian cancer.

Authors:  Barbara A Goff; Barbara J Matthews; Eric H Larson; C Holly A Andrilla; Michelle Wynn; Denise M Lishner; Laura-Mae Baldwin
Journal:  Cancer       Date:  2007-05-15       Impact factor: 6.860

10.  Ovarian cancer, version 3.2012.

Authors:  Robert J Morgan; Ronald D Alvarez; Deborah K Armstrong; Robert A Burger; Mariana Castells; Lee-may Chen; Larry Copeland; Marta Ann Crispens; David Gershenson; Heidi Gray; Ardeshir Hakam; Laura J Havrilesky; Carolyn Johnston; Shashikant Lele; Lainie Martin; Ursula A Matulonis; David M O'Malley; Richard T Penson; Steven W Remmenga; Paul Sabbatini; Joseph T Santoso; Russell J Schilder; Julian Schink; Nelson Teng; Theresa L Werner; Miranda Hughes; Mary A Dwyer
Journal:  J Natl Compr Canc Netw       Date:  2012-11-01       Impact factor: 11.908

View more
  16 in total

1.  Demographic, presentation, and treatment factors and racial disparities in ovarian cancer hospitalization outcomes.

Authors:  Tomi F Akinyemiju; Gurudatta Naik; Kemi Ogunsina; Daniel T Dibaba; Neomi Vin-Raviv
Journal:  Cancer Causes Control       Date:  2018-02-10       Impact factor: 2.506

2.  Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

Authors:  Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

3.  Contribution of Geographic Location to Disparities in Ovarian Cancer Treatment.

Authors:  Carolina Villanueva; Jenny Chang; Scott M Bartell; Argyrios Ziogas; Robert Bristow; Verónica M Vieira
Journal:  J Natl Compr Canc Netw       Date:  2019-11-01       Impact factor: 11.908

4.  Impact of Race, Ethnicity, and Socioeconomic Status on Nasopharyngeal Carcinoma Disease-Specific and Conditional Survival.

Authors:  Ashley O London; Liam W Gallagher; Rahul K Sharma; Daniel Spielman; Justin S Golub; Jonathan B Overdevest; Carol H Yan; Adam DeConde; David A Gudis
Journal:  J Neurol Surg B Skull Base       Date:  2021-12-29

5.  Socioeconomic Disparities in Brain Metastasis Survival and Treatment: A Population-Based Study.

Authors:  Adrian Rodrigues; Guan Li; Hriday Bhambhvani; Melanie Hayden-Gephart
Journal:  World Neurosurg       Date:  2021-11-14       Impact factor: 2.210

6.  Ovarian cancer in California: Guideline adherence, survival, and the impact of geographic location, 1996-2014.

Authors:  Carolina Villanueva; Jenny Chang; Argyrios Ziogas; Robert E Bristow; Verónica M Vieira
Journal:  Cancer Epidemiol       Date:  2020-10-03       Impact factor: 2.984

7.  Regional Disparities in Ovarian Cancer in the United States.

Authors:  Zhixin Wang; Sarah Dilley; HyounKyoung G Park; Alfred A Bartolucci; Chenguang Wang; Warner K Huh; Sejong Bae
Journal:  Cancer Health Disparities       Date:  2019-08-19

8.  Guideline-adherent treatment, sociodemographic disparities, and cause-specific survival for endometrial carcinomas.

Authors:  Victoria E Rodriguez; Alana M W LeBrón; Jenny Chang; Robert E Bristow
Journal:  Cancer       Date:  2021-03-15       Impact factor: 6.921

Review 9.  Disparities in Gynecological Malignancies.

Authors:  Sudeshna Chatterjee; Divya Gupta; Thomas A Caputo; Kevin Holcomb
Journal:  Front Oncol       Date:  2016-02-22       Impact factor: 6.244

10.  Cervical Cancer Care Continuum in South India: Evidence from a Community-based Screening Program.

Authors:  E Vidhubala; K Niraimathi; Hemant Deepak Shewade; Sankar Mahadevan
Journal:  J Epidemiol Glob Health       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.